Back to top

Analyst Blog

Aradigm Corporation (ARDM) recently announced the closing of an exclusive, worldwide license agreement with Grifols, S.A. (GRFS - Snapshot Report) for the development and commercialization of Aradigm’s proprietary formulations of the antibiotic ciprofloxacin (Pulmaquin and Lipoquin). These formulations are being developed for managing infections associated with severe respiratory diseases -- cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis (BE), and are administered through inhalation.

As per the agreement, the companies will focus on advancing the ciprofloxacin formulations into phase III studies on BE. Grifols will bear the development expenses of up to $65 million for the BE indication and Aradigm will receive milestone payments of up to $25 million.

Furthermore, Aradigm will receive tiered royalties from Grifols on worldwide sales of products which comprise Aradigm’s ciprofloxacin formulations. Grifols also has the choice to license Aradigm's pulmonary drug delivery platform (AERx) for use with another molecule, along with bearing the responsibility for all commercialization activities.

Grifols also acquired a 35% stake by purchasing Aradigm’s common stock at $0.124 per share amounting to a total investment of $26 million.

We note that Lipoquin has orphan drug designation for CF in the U.S. and EU, and for BE in the U.S. Pulmaquin also has orphan drug status for BE in the U.S.

As far as BE is concerned, Aradigm has successfully completed a phase IIa study on Lipoquin, along with a phase IIb study on Lipoquin and Pulmaquin each. For the indication of CF, the company has completed a successful phase IIa study on Lipoquin.

Presently, Aradigm carries a Zacks Rank #3 (Hold). Currently, companies which look attractive include Gilead Sciences Inc. (GILD - Analyst Report) and Jazz Pharmaceuticals (JAZZ - Analyst Report) with a Zacks Rank #1 (Strong Buy) and a Zacks Rank #2 (Buy), respectively.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ERBA DIAGNO… ERB 3.81 +7.32%
BANCO DO BR… BDORY 14.49 +3.87%
WEATHERFORD… WFT 23.80 +3.77%
EQT MIDSTRE… EQM 97.46 +2.67%
GREEN PLAIN… GPRE 44.97 +2.65%